Publications

Sriram U, Wong M, Caillier SJ, Hecht FM, Elkins MK, Levy JA, Oksenberg JR, Baranzini SE. Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy. AIDS research and human retroviruses. 2007. PMID: 17531001


Jay Levy, MD

Fong L, Small EJ. Immunotherapy for prostate cancer. Current oncology reports. 2007. PMID: 17430695


Lawrence Fong, MD

Fong L, Small EJ. Immunotherapy for prostate cancer. Current oncology reports. 2007. PMID: 17430695


Eric Small, MD

Lin AM, Small EJ. Prostate cancer update: 2006. Current opinion in oncology. 2007. PMID: 17414641


Amy Lin, MD

Lin AM, Small EJ. Prostate cancer update: 2006. Current opinion in oncology. 2007. PMID: 17414641


Eric Small, MD

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007. PMID: 17471238


Mark Moasser, MD

Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Investigational new drugs. 2007. PMID: 17458505


Eric Small, MD

Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes & development. 2007. PMID: 17437992


John Gordan, MD, PhD

Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Volume 22 of Issue 5 Movement disorders : official journal of the Movement Disorder Society. 2007. PMID: 17266075


Andrew Ko, MD

Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD. Analysis of PALB2/FANCN-associated breast cancer families. Proceedings of the National Academy of Sciences of the United States of America. 2007. PMID: 17420451


Alan Ashworth, PhD

Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. PMID: 17404083


Eric Small, MD

Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer cell. 2007. PMID: 17418410


John Gordan, MD, PhD

Barbour JD, Sriram U, Caillier SJ, Levy JA, Hecht FM, Oksenberg JR. Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS pathogens. 2007. PMID: 17447840


Jay Levy, MD

Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematology/oncology clinics of North America. 2007. PMID: 17512451


Hope Rugo, MD

Rugo HS. Hormonal therapy for advanced breast cancer. Hematology/oncology clinics of North America. 2007. PMID: 17512449


Hope Rugo, MD

Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Molecular pharmacology. 2007. PMID: 17392524


John Park, MD

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics. 2007. PMID: 17363191


Alan Venook, MD

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics. 2007. PMID: 17363191


Emily Bergsland, MD

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics. 2007. PMID: 17363191


Margaret Tempero, MD

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics. 2007. PMID: 17363191


Andrew Ko, MD